bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
275 hedge funds and large institutions have $3.41B invested in bluebird bio in 2020 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 100 increasing their positions, 85 reducing their positions, and 42 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 85
3% more call options, than puts
Call options by funds: $55.7M | Put options by funds: $54.3M
0.31% less ownership
Funds ownership: 7.69% → 7.39% (-0.31%)
5% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 42
1% less funds holding
Funds holding: 278 → 275 (-3)
13% less capital invested
Capital invested by funds: $3.94B → $3.41B (-$526M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$20.5M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$15.9M |
| 3 |
AC
Armistice Capital
New York
|
+$14M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.5M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$46.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$22.9M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$22.1M |
| 5 |
Goldman Sachs
New York
|
-$17.9M |
BLUE Hedge Fund Activity: Q3 2020 in Review
275 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2020, worth a combined $3.41B — down 13% from $3.94B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of BLUE and 40 opened new positions — a net loss of 2 holders — while 85 trimmed existing stakes and 100 added.
The largest buyer was Massachusetts Financial Services, opening a new position worth an estimated $20.5M. The largest seller was Fidelity Investments, cutting an estimated $46.9M.
- 275 institutional investors held bluebird bio (BLUE) as of Q3 2020, down from 278 in Q2 2020.
- Funds reported $3.41B of bluebird bio stock for Q3 2020, down 13% quarter-over-quarter.
- 40 funds opened new bluebird bio positions in Q3 2020 and 42 closed out, a net change of -2 holders.
- The largest bluebird bio buyer in Q3 2020 was Massachusetts Financial Services, an estimated $20.5M added.
- The largest bluebird bio seller in Q3 2020 was Fidelity Investments, an estimated $46.9M sold.
Based on aggregated 13F filings for Q3 2020.